The Medium Obtained from the Culture of Hodgkin Lymphoma Cells Affects the Biophysical Characteristics of a Fibroblast Cell Model.
3D model
Hodgkin lymphoma
cell culture
fibroblasts
lymphoma
tumor microenvironment
Journal
Bioengineering (Basel, Switzerland)
ISSN: 2306-5354
Titre abrégé: Bioengineering (Basel)
Pays: Switzerland
ID NLM: 101676056
Informations de publication
Date de publication:
03 Feb 2023
03 Feb 2023
Historique:
received:
27
12
2022
revised:
20
01
2023
accepted:
28
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
The neoplastic Hodgkin-Reed-Sternberg (HRS) cells in Hodgkin lymphoma (HL) represent only 1-10% of cells and are surrounded by an inflammatory microenvironment. The HL cytokine network is a key point for the proliferation of HRS cells and for the maintenance of an advantageous microenvironment for HRS survival. In the tumor microenvironment (TME), the fibroblasts are involved in crosstalk with HRS cells. The aim of this work was to study the effect of lymphoma cell conditioned medium on a fibroblast cell population and evaluate modifications of cell morphology and proliferation. Hodgkin lymphoma-derived medium was used to obtain a population of "conditioned" fibroblasts (WS-1 COND). Differences in biophysical parameters were detected by the innovative device Celector
Identifiants
pubmed: 36829691
pii: bioengineering10020197
doi: 10.3390/bioengineering10020197
pmc: PMC9952528
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Haematologica. 2004 Jun;89(6):679-85
pubmed: 15194535
Biotechnol J. 2008 Oct;3(9-10):1172-84
pubmed: 18566957
Bioengineering (Basel). 2022 Jan 22;9(2):
pubmed: 35200403
Int J Biochem Cell Biol. 2005 Mar;37(3):511-7
pubmed: 15618006
Assay Drug Dev Technol. 2014 May;12(4):207-18
pubmed: 24831787
J Hematol Oncol. 2013 Aug 29;6:62
pubmed: 23988031
Nat Rev Dis Primers. 2020 Jul 23;6(1):61
pubmed: 32703953
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Haematologica. 2022 Jan 01;107(1):287-291
pubmed: 34498447
J Clin Invest. 2012 Oct;122(10):3439-47
pubmed: 23023715
Int J Cancer. 2009 Sep 1;125(5):1092-101
pubmed: 19391137
J Clin Oncol. 2011 May 10;29(14):1812-26
pubmed: 21483001
Blood. 1999 Sep 15;94(6):2065-71
pubmed: 10477736
Leuk Lymphoma. 1992 Jul;7(4):297-303
pubmed: 1493429
Blood. 2008 Feb 15;111(4):2339-46
pubmed: 18070985
Aging (Albany NY). 2017 Dec 28;9(12):2666-2694
pubmed: 29283887
Adv Anat Pathol. 2014 Jan;21(1):12-25
pubmed: 24316907
Semin Cancer Biol. 2015 Oct;34:14-21
pubmed: 25725205
Nat Rev Cancer. 2006 May;6(5):392-401
pubmed: 16572188
Cancers (Basel). 2015 Dec 11;7(4):2443-58
pubmed: 26690480
Cancers (Basel). 2021 Jul 20;13(14):
pubmed: 34298847
Histopathology. 2001 Apr;38(4):368-75
pubmed: 11318902
Blood. 2015 Sep 10;126(11):1394-7
pubmed: 26228484
Cancers (Basel). 2021 Mar 19;13(6):
pubmed: 33808627
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Int J Mol Sci. 2019 May 15;20(10):
pubmed: 31096713
Cancers (Basel). 2020 Feb 03;12(2):
pubmed: 32028697
J Exp Med. 1999 Jun 21;189(12):1939-46
pubmed: 10377189
Stem Cell Rev Rep. 2009 Dec;5(4):420-7
pubmed: 20058204
Blood. 2002 Jun 15;99(12):4283-97
pubmed: 12036854
Int J Cancer. 2008 Feb 15;122(4):769-76
pubmed: 17935139
Mol Cancer. 2021 Oct 11;20(1):131
pubmed: 34635121
Cancer Lett. 2016 Sep 28;380(1):243-52
pubmed: 26474544
Cancers (Basel). 2019 Oct 30;11(11):
pubmed: 31671543
Cancer Res. 1992 Jun 15;52(12):3353-60
pubmed: 1596893
Leuk Lymphoma. 2012 Feb;53(2):195-201
pubmed: 21756027
Clin Lymphoma Myeloma. 2009 Jun;9(3):206-16
pubmed: 19525189
Biochim Biophys Acta. 2013 Jul;1832(7):1070-8
pubmed: 23123598
Nat Rev Cancer. 2009 Jan;9(1):15-27
pubmed: 19078975